Morgan Stanley resumed coverage on Centene with a new price target
$CNC
Medical Specialities
Health Care
Morgan Stanley resumed coverage of Centene with a rating of Overweight and set a new price target of $70.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/9/2025 | $70.00 | Overweight | Morgan Stanley |
| 6/2/2025 | $65.00 | Overweight → Equal Weight | Barclays |
| 4/8/2025 | $64.00 | Underperform → Hold | Jefferies |
| 2/6/2025 | Buy → Hold | Argus | |
| 12/17/2024 | $80.00 → $75.00 | Overweight | Analyst |
| 12/13/2024 | $79.00 → $80.00 | Neutral → Buy | UBS |
| 12/10/2024 | $68.00 → $52.00 | Hold → Underperform | Jefferies |
| 7/24/2024 | $83.00 → $69.00 | Buy → Hold | Jefferies |
4 - CENTENE CORP (0001071739) (Issuer)
4 - CENTENE CORP (0001071739) (Issuer)
4 - CENTENE CORP (0001071739) (Issuer)
Morgan Stanley resumed coverage of Centene with a rating of Overweight and set a new price target of $70.00
Barclays downgraded Centene from Overweight to Equal Weight and set a new price target of $65.00
Jefferies upgraded Centene from Underperform to Hold and set a new price target of $64.00
S-8 - CENTENE CORP (0001071739) (Filer)
8-K - CENTENE CORP (0001071739) (Filer)
SCHEDULE 13G - CENTENE CORP (0001071739) (Subject)
Board further strengthened with appointment of Mike McFarland as Director National Veterinary Associates Group ("NVA"), a leading veterinary care organization, today announced it has strengthened its Board with the appointments of Ken Burdick as Executive Chairman and Dr. James "Mike" McFarland as Director. These executives bring substantial healthcare and public company experience ahead of the company's future IPO. Burdick is a seasoned public company executive with more than 40 years of healthcare experience. He currently serves as Executive Chairman at LifeStance Health (NASDAQ:LFST), a leading U.S. provider of outpatient mental healthcare. Since joining LifeStance as Chairman and CEO
ST. LOUIS, Feb. 24, 2025 /PRNewswire/ -- Centene Corporation (NYSE:CNC) ("the Company") announced today the appointment of Kenneth Y. Tanji to the Centene Board of Directors, effective February 20, 2025. Mr. Tanji will serve on the Company's Audit and Compliance Committee. The appointment of Mr. Tanji expands Centene's Board of Directors to 12 members. Mr. Tanji's finance acumen spans more than three decades and includes deep knowledge of capital optimization strategies, strategic acquisitions, JV partnership models and the use of advanced analytics and technologies to scale g
New leadership role reflects Centene's focus on ICHRA growth ST LOUIS, Jan. 9, 2025 /PRNewswire/ -- Centene Corporation ("Centene") (NYSE:CNC), a leading healthcare enterprise committed to helping people live healthier lives, is pleased to announce that Alan Silver has joined the organization as the President of its Ambetter Health Solutions business, which focuses on ICHRA (Individual Coverage Health Reimbursement Arrangements). This newly created role reflects Centene's belief that consumers increasingly will seek health insurance that offers transparency, customization, choice and convenience. ICHRA plans allow employees to shop on the individual Marketplace and choose the insurance plan
4 - CENTENE CORP (0001071739) (Issuer)
4 - CENTENE CORP (0001071739) (Issuer)
4 - CENTENE CORP (0001071739) (Issuer)